RESUMO
Objective:To investigate the effects of Zhibitai capsule combined with pitavastatin calcium tablets on blood lipids, blood glucose, and glycated hemoglobin in patients with coronary heart disease complicated by diabetes mellitus. Methods:A total of 100 patients with coronary heart disease and diabetes mellitus who received treatment in The Third Affiliated Hospital of Jinzhou Medical University from January 2017 to June 2020 were included in this study. They were divided into a control group ( n = 50) and an observation group ( n = 50) according to different treatment methods. Both groups were given conventional treatment such as pitavastatin calcium tablets. The control group was given pitavastatin calcium tablets based on conventional treatment. The observation group was given Zhibitai capsule combined with pitavastatin calcium tablets based on conventional treatment. After 6 months of treatment, serum levels of triacylglycerol, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, and glycated hemoglobin were compared between the two groups. Results:After treatment, serum levels of triacylglycerol, total cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, glycated hemoglobin in the observation group were (4.26 ± 0.67) mmol/L, (1.85 ± 0.38) mmol/L, (3.16 ± 0.27) mmol/L, (8.29 ± 1.07) mmol/L, and (8.20 ± 0.77)%, respectively, and they were (4.50 ± 0.39) mmol/L, (1.99 ± 0.19) mmol/L, (3.28 ± 0.27) mmol/L, (8.80 ± 0.66) mmol/L, (8.54 ± 0.74)%, respectively in the control group. After treatment, these indices in each group were decreased compared with those before treatment (control group: t = 19.56, 14.60, 10.66, 8.60, 10.18; observation group: t = 15.04, 14.68, 11.36, 12.36, 12.89, all P < 0.05). After treatment, these indices in the observation group were significantly lower than those in the control group ( t = -2.12, -2.23, 2.26, -2.84, -2.44, all P < 0.05). After treatment, the level of high-density lipoprotein cholesterol in the observation and control groups was (1.16 ± 0.18) mmol/L and (1.09 ± 0.13) mmol/L, respectively. After treatment, the level of high-density lipoprotein cholesterol in each group was increased compared with that before treatment (control group: t = -11.10, observation group: t = -11.07, P < 0.05). After treatment, the level of high-density lipoprotein cholesterol in the observation group was significantly higher than that in the control group ( t = 2.11, P < 0.05). Conclusion:Zhibitai capsule combined with pitavastatin calcium tablets can greatly improve the level of blood lipids and blood glucose in patients with coronary heart disease complicated by diabetes mellitus.
RESUMO
Objective:To observe the clinical efficacy of Zhibitai capsule in the treatment of dyslipidemia with phlegm-stasis binding pattern, in order to evaluate its effectiveness and safety. Method:Totally 82 patients of dyslipidemia with phlegm-stasis binding pattern were selected from the outpatient department of internal medicine in Hospital of Xidian University from July 2018 to July 2019. According to the random number table method, they were divided into control group and observation group, with41 cases in each group. Control group was treated with aAtorvastatin calcium, and observation group was treated with Zhibitai capsules. The changes in blood lipid index, liver function and renal function were measured before and after 8-week treatment in two groups, the efficacy on traditional Chinese medicine (TCM) syndromes and clinical symptom scores before and after treatment were compared between two groups, and the adverse reactions, such as liver pain and muscle pain, were recorded among patients. Result:The changes of blood lipids were compared after 8 weeks of treatment, total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were all lower than before, while high-density lipoprotein cholesterol (HDL-C) was increased (P<0.05), the total effective rate in control group was 90.24% (37/41), which was 92.68% (38/41) in observation group, with no significant difference between two groups, in the TCM syndrome scores of two groups before and after treatment, four common TCM syndromes, namely scores dizziness, chest tightness, head heavy as if swathed and chest fullness, were decreased (P<0.05). In terms of the efficacy of two groups of TCM syndromes, the total effective rate in control group was 87.80% (36/41), which was 92.68% (38/41) in observation group, with no statistically significant difference between two groups. Control group had 3 cases of increased transaminase, but none of them beyond 2 times of the normal upper limit, and observation group had 1 case of mild abdominal distension and nausea, which did not affect continued medication. No muscle pain or liver pain occurred in two groups. Conclusion:Zhibitai capsule is effective in treating dyslipidemia, which is comparable to atorvastatin calcium in treating dyslipidemia, with the safety and reliability.
RESUMO
Objective To observe the influence of Zhibitai capsule combined with atorvastatin calcium tablet on blood lipid and inflammatory factors in elder patients with dyslipidemia. Methods Sixty-four elder patients with dyslipidemia were randomly divided into control group and treatment group, with 32 cases in each group. Patients of the control group were treated with atorvastatin calcium tablet (10 mg, qd, bedtime administration), while patients in the treatment group were given Zhibitai capsule (240 mg, bid) for 6 weeks. Serum levels of TC, TG, HDL-C, LDL-C, tumor necrosis factor-alpha ( TNF-α) and interleukin-6 (IL-6) were measured before and after treatment. Results After treatment, compared with the control group, TC [(5. 18±0. 57) mmol·L-1 vs. (5. 73±0. 65)mmol·L-1], TG [(1. 52±0. 43) mmol·L-1 vs. (1. 86±0. 48) mmol·L-1], LDL-C [(3. 36±0. 48) mmol·L-1 vs. (3. 85±0. 53)mmol·L-1], TNF-α[(5. 37±2. 21) ng·L-1 vs. (7. 63±2. 59) ng·L-1] and IL-6 [(12.27±2.75) ng·L-1 vs. (15. 63±2. 92) ng·L-1] were significantly decreased (P<0. 01 for all); however, HDL-C [(1. 26±0. 25) mmol·L-1 vs. (1. 13±0. 23) mmol·L-1] was significantly increased in the patients of treatment group (P<0. 05). Conclusion Zhibitai capsule combined with atorvastatin calcium tablet may not only regulate blood lipid level, but also decrease serum tumor necrosis factor-alpha and interleukin-6 so as to inhibit inflammation reaction in elder patients with dyslipidemia.
RESUMO
Objective To explore the effect of Zhibitai capsule in the treatment of elderly coronary artery disease patients with normal lipid,and to investigate its influence on prognosis.Methods 90 elderly coronary artery disease patients with normal lipid were randomly divided into the control group (n =30),the treatment group 1 (n =30) and the treatment group 2 (n =30).The control group received routine treatment,once a day for 2 months.The treatment group 1 received the Xuezhikang capsule,once a day for 2 months.The treatment group 2 received the Zhibitai capsule,once a day for 2 months.The expression of inflammatory factors,the level of blood fat,the maintenance rate of sinus rhythm and the incidence rate of embolism before and after treatment were compared among the three groups.Results After treatment,the levels of hs-CRP,IL-6,TNF-α,TC,TG,LDL-C of the three groups were significantly lower than those before treatment(P ＜ 0.05),and the level of HDL-C was significantly higher than before treatment (P ＜ 0.05).The levels of hs-CRP,IL-6,TNF-α,TC,TG,LDL-C in the treatment group 2 were significantly lower and the level of HDL-C was significantly higher than the other two goups (P ＜ 0.05).Moreover,the differences between the control group and the treatment group 1 were not statistically significant.The maintenance rate of sinus rhythm of the treatment group 2 was significantly higher and the incidence rate of embolism was significantly lower than the treatment group 1.Conclusion For elderly coronary artery disease patients with normal lipid,the Zhibitai capsule has ideal effect in controlling inflammation,which can delay the progress of atherosclerosis,decrease the major cardiovascular events and better than the Xuezhikang capsule.